Trachsel, Belinda http://orcid.org/0000-0002-5177-4167
Imobersteg, Stefan
Valpreda, Giulia
Singer, Gad http://orcid.org/0000-0001-8090-7267
Grabherr, Regula
Ormos, Mark
Burger, Irene A. http://orcid.org/0000-0001-8029-8692
Kubik-Huch, Rahel A. http://orcid.org/0000-0002-3636-8697
Schibli, Roger http://orcid.org/0000-0002-1537-3833
Vogel, Viola http://orcid.org/0000-0003-2898-7671
Béhé, Martin http://orcid.org/0000-0002-1110-2665
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_179342)
Article History
Received: 24 December 2023
Accepted: 24 January 2024
First Online: 10 February 2024
Declarations
:
: Animal experiments described in this study were conducted in line with the Swiss Law on animal experimentation and were approved by the veterinary office of the canton of Aargau, Switzerland under the licence number AG75700. Due to the explorative character of the study not all ARRIVE guidelines could be implemented from study start, however animal experiments are clearly reported according to the standards set out by the ARRIVE guidelines. The use of human tissues for this study was approved by the ethics committee of the Kantonsspital Baden and participants provided informed written consent. Written and informed consent was obtained from all study participants.
: Endometriosis patients provided informed consent for publication of the images in Fig. InternalRef removed and in Additional file InternalRef removed: Fig. S5.
: MB, VV and RS hold a patent (Patent Number: 11649268) covering the use of fibronectin-binding peptides in the diagnosis and therapy of fibrosis and tumors. IAB is “Editor-in-Chief” of the EJNMMI Res, but was not involved in the review process of this paper.